Pfenex (PFNX) Stock Price, News & Analysis

Company Overview

Pfenex Inc. was a biopharmaceutical company focused on developing and commercializing complex protein therapeutics, biosimilars and other biologic products. The company used its proprietary Pfenex Expression Technology platform, based on microbial protein expression, to support the development and manufacturing of recombinant proteins and other biologic medicines.

Pfenex’s lead commercial product was Bonsity, a teriparatide injection used to treat osteoporosis in certain patients at high risk of fracture. The company also developed additional protein-based therapies and biosimilar candidates, often through collaborations with pharmaceutical partners. Its products and partnerships were directed primarily toward the U.S. market, with potential international applications through licensing and commercialization agreements.

Pfenex was led by President and Chief Executive Officer Eef Schimmelpennink during its period as an independent public company. Ligand Pharmaceuticals completed its acquisition of Pfenex in 2021, after which Pfenex ceased operating as a standalone publicly traded company and its assets and programs became part of Ligand’s portfolio.

Key Stats

• Today's Range: $12.75 to $12.75
• 50-Day Range: $12.75 to $12.75
• 52-Week Range: $5.26 to $14.00
• Volume: N/A
• Average Volume: 503,865 shs
• Market Capitalization: $437.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/07/2020
• Today: 10/04/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSEAMERICAN:PFNX
• Previous Symbol: NYSEMKT:PFNX
• CIK: N/A
• Web: www.pfenex.com
• Phone: +1-858-3524400
• Fax: N/A
• Employees: 71
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 34,297,000
• Free Float: N/A
• Market Cap: $437.29 million
• Optionable: Not Optionable
• Beta: N/A